Replies to post #884 on Bioxytran Inc (BIXT)

[Ecomike]

$BIXT opportunities:

1) Bloomberg stated in a November 1st article on long COVID that "at least 140 million people worldwide are suffering with long COVID and Harvard University economist David Cutler puts the total cost of long Covid in the US at $3.7 trillion**. That's equal to more than 80% of government outlays for the pandemic through the end of July. And scientists still don't know what causes it, how many people it affects, or how to prevent and treat it."

[Ecomike]

You folks need to read this. This could set a fire under $BIXT

Only 2 perfect clinical trials in the past decade

https://www.linkedin.com/pulse/mythbusting-quest-perfect-clinical-trial-michael-sheikh/

"When we at Bioxytran got our clinical trial results back I was astounded because I had never seen a perfect clinical trial in all my years in biotech. Being the diligent researcher that I am, I tried to find one but none of the search terms yielded any fruit. Then I narrowed the search looking for a 100% response rate. I found it, the other perfect clinical trial this past decade."

"Gilead Sciences purchased Pharmasset for $11.0 billion to get their at-the-time promising Phase 3 ready Hepatitis C (HCV) asset in 2011. They had a perfect 21/21 response rate for sustained virological response 12 weeks after treatment (SVR12)."

"Now, this was an open-label trial with no control, but the endpoint was SVR12 which is a proxy for the complete elimination of the virus. They enrolled 100 participants separated out by the severity of HCV; some had never had treatment and others had failed the standard of care. Across the board the results were phenomenal and two of the five cohorts had a perfect score."

"Gilead’s HCV drug is now known as Harvoni, and many refer to it as a cure for Hepatitis C as it was extremely efficacious across HCV genotypes, referred to as pan-genotypic. Harvoni (sofosbuvir) interferes with two proteins involved in the viral life cycle, preventing the replication of virions. The treatment uses sofosbuvir which is an NS5B inhibitor and a second molecule called ledipasivir which is a NS5A inhibitor. The Mechanism of Action (MOA) of these antiviral is through protease inhibition which stops the viral replication. Ledipasvir is an inhibitor of the HCV NS5A protein, which is a non-enzymatic, nonstructural protein required for viral replication. Sofosbuvir, on the other hand, is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which helps make new RNA for the new virions."

The rest of the article is on that link on LinkedIn